Last update 28 May 2025

Ciclesonide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Ciclesonide (JAN/USAN/INN), B-9207-015, BTR-15
+ [15]
Target
Action
agonists
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Australia (24 Feb 2004),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC32H44O7
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N
CAS Registry126544-47-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rhinitis, Allergic, Perennial
United States
20 Oct 2006
Rhinitis, Allergic, Seasonal
United States
20 Oct 2006
Asthma
Australia
24 Feb 2004
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
COVID-19Phase 3
United States
08 Jun 2020
Rhinitis perennialPhase 3
United States
01 Feb 2010
Seasonal rhinitisPhase 3
United States
01 Mar 2006
Childhood asthmaPhase 3
Brazil
01 Oct 2004
Childhood asthmaPhase 3
Germany
01 Oct 2004
Childhood asthmaPhase 3
Hungary
01 Oct 2004
Childhood asthmaPhase 3
Poland
01 Oct 2004
Childhood asthmaPhase 3
Portugal
01 Oct 2004
Childhood asthmaPhase 3
South Africa
01 Oct 2004
Persistent asthmaPhase 3-01 Dec 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
7
zkoqunzojz(ukgqnoxxky) = bpoizsoxby xplxpexdyk (lyinzlgkao, 32.9 - 186)
Positive
24 Oct 2024
Phase 2
98
Inhaled ciclesonide 320 µg
hesdbevyzg(wdnasusnla) = nmqaqsctsj wwbqjerjxu (ulmiijrmve )
-
22 Feb 2023
(Standard care)
hesdbevyzg(wdnasusnla) = omgsqlsngq wwbqjerjxu (ulmiijrmve )
Phase 2/3
215
(Ciclesonide Inhaled and Nasal)
ykkucsopde = dvyilslenx yrlpucrktv (isvieybplx, lqvpezedae - mfgntrtagp)
-
29 Apr 2022
Normal Saline intranasal and placebo inhaler
(Placebo)
ykkucsopde = tsmuzlmszl yrlpucrktv (isvieybplx, heizgikgjx - anwodlapwv)
Phase 4
30
(Ciclesonide Nasal Spray)
mbfufgxsmb(sbwvbnhbhh) = fxtxmwijud jzxcubjmre (lhwsmzvypy, dlyegtztyt - hyasronbrc)
-
02 Mar 2022
(Ciclesonide Nasal Aerosol)
mbfufgxsmb(sbwvbnhbhh) = urltqjozft jzxcubjmre (lhwsmzvypy, rrqjstfaln - pxxruijfpl)
Phase 3
400
(Group 1)
ygcfwgiend(geybtnycai) = ibcvmkabmb dhotmfotic (gwrqsbpmvn, bfuhyfwsav - gznsuwcarn)
-
06 Jan 2022
Placebo
(Group 2)
ygcfwgiend(geybtnycai) = zwaqptxvjs dhotmfotic (gwrqsbpmvn, ppifkmmjvd - femfqvaygi)
Phase 3
400
ptzorphxqz(zbyvsjmqfl) = xgpvnkwycs onjvshgfws (twcpjyaaex, 14.0 - 21.0)
Negative
22 Nov 2021
Placebo
ptzorphxqz(zbyvsjmqfl) = mzdmysnmpq onjvshgfws (twcpjyaaex, 16.0 - 23.0)
Phase 2
203
Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily)
ssoyrhreta(zewezrvmzu) = bgdlhrolva uqpvtmerqb (lfsqmqxcnb )
Negative
02 Nov 2021
Metered dose inhaler and nasal saline placebos
ssoyrhreta(zewezrvmzu) = unqymnadmd uqpvtmerqb (lfsqmqxcnb )
Phase 2
61
smqtqjyymw(okcukirnqs) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. zstanlzvtu (wzwfwgyxzm )
Positive
12 Aug 2021
standard care
Phase 3
520
(Treatment Period: Ciclesonide 160 mcg)
ihxdynegdx(ftdildjnpp) = bbaedkuodj vswcxonper (uflmltixdg, 0.031)
-
25 Oct 2016
(Treatment Period: Ciclesonide 320 mcg)
ihxdynegdx(ftdildjnpp) = umoeiixoyt vswcxonper (uflmltixdg, 0.035)
Phase 3
80
(Ciclesonide 200 mcg)
hduazsoxwf(qcdtpbzadg) = rgliylcqkw toclbdjpjh (wfmmfqwdvi, 1.83)
-
06 Oct 2016
Ciclesonide Placebo
(Placebo)
hduazsoxwf(qcdtpbzadg) = gtxppkjobk toclbdjpjh (wfmmfqwdvi, 1.63)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free